Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study

Neurogastroenterol Motil. 2021 Jan;33(1):e13953. doi: 10.1111/nmo.13953. Epub 2020 Aug 9.

Abstract

Background: Previous studies suggest that specific genes may predispose some to increased risk of dysphagia in the geriatric population, but whether these genes may affect swallowing recovery after a stroke is unknown. This study investigated whether single-nucleotide polymorphisms (SNP) of the brain-derived neurotrophic factor (BDNF), catechol-O-methyl transferase, apolipoprotein E, interleukin-1 receptor antagonist, and dopamine, which have been linked to swallowing, could adversely affect the prognosis of post-stroke dysphagia.

Methods: In this study, 218 subjects with confirmed post-stroke dysphagia were enrolled. The primary endpoint was failed recovery from nil per mouth (NPM) status with the first 3 months post-stroke.

Key results: The Val/Val group from the rs6265, BDNF, showed higher score changes on the Functional Oral Intake Scale at 1 month. The proportion of patients with recovery from NPM status within the first 1 month was 60.8% in the Val/Val group, which was statistically higher than those in the Met allele groups (38.1%, P = .017). At 3 months, the BDNF rs6265 showed significant group differences in Modified Barium Swallow Impairment Profile© score changes with the Val/Val allele leading to greater improvement. However, no single SNP was associated with increased risk of poor recovery with persistence of NPM at 3 months post-stroke.

Conclusions and inferences: Those with the dominant Val/Val phenotype of BDNF manifested with faster and greater improvement than the Met-phenotypes. Based on our results, the BDNF Val allele may play a positive role with faster score improvement and rapid recovery from NPM than the Met allele. Clinical Trials gov: NCT03577444 (https://clinicaltrials.gov/ct2/show/study/NCT03577444).

Keywords: brain-derived neurotrophic factor; deglutition disorders; genotype; prognosis; single-nucleotide polymorphism; stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Apolipoproteins E / genetics
  • Brain-Derived Neurotrophic Factor / genetics*
  • Catechol O-Methyltransferase / genetics
  • Cohort Studies
  • Deglutition Disorders / etiology
  • Deglutition Disorders / physiopathology*
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / genetics
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Prospective Studies
  • Receptors, Dopamine D1 / genetics
  • Receptors, Dopamine D2 / genetics
  • Recovery of Function / genetics*
  • Stroke / complications
  • Stroke / physiopathology*

Substances

  • ApoE protein, human
  • Apolipoproteins E
  • Brain-Derived Neurotrophic Factor
  • DRD1 protein, human
  • DRD2 protein, human
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • BDNF protein, human
  • COMT protein, human
  • Catechol O-Methyltransferase

Associated data

  • ClinicalTrials.gov/NCT03577444